Ascentage Pharma Group International vs Emergent BioSolutions
AAPG and EBS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and EBS compare
Emergent BioSolutions grew revenue faster over the last twelve months (−17.7% versus −41.5% for Ascentage Pharma Group International).
Emergent BioSolutions keeps more of each dollar of sales as profit, with a net margin of −40.2% compared with −216% at Ascentage Pharma Group International.
Emergent BioSolutions scores higher on the StockData Score (7 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | EBS |
|---|---|---|
| Size and price | ||
| Market cap | – | $310M |
| Share price | $15.00 | $6.04 |
| Change, 1 year | −53.7% | −45.0% |
| Change, 5 years | – | −84.9% |
| Beta (5Y) | 0.81 | 1.85 |
| Employees | 767 | 900 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.5× |
| P/B | – | 1.0× |
| P/FCF | – | 1.6× |
| FCF yield | – | 60.8% |
| Fair value | – | $21.23 |
| Margin of safety | – | 71.5% |
| Growth | ||
| Revenue growth (TTM) | −41.5% | −17.7% (better) |
| Revenue growth, 5Y average | – | −14.0% |
| Net income growth (TTM) | – | −443% |
| EPS growth (TTM) | – | −486% |
| EPS growth, 5Y average | – | −30.4% |
| Profitability | ||
| Gross margin | 91.5% (better) | 48.4% |
| Operating margin | – | −27.7% |
| Net margin | −216% | −40.2% (better) |
| FCF margin | −209% | 29.0% (better) |
| Return on equity | −156% | −58.2% (better) |
| Return on invested capital | – | −17.3% |
| Financial health | ||
| Debt / equity | 1.50 (better) | 1.62 |
| Interest coverage | – | −4.0× |
| Current ratio | 1.79 | 4.58 (better) |
| Altman Z-score | – | 0.34 |
| Piotroski F-score | – | 7 |
| Dividends and buybacks | ||
| Buyback yield | – | 8.8% |
| Shareholder yield | – | 8.8% |
| Ownership | ||
| Held by institutions | 0.00% | 87.1% |
| Held by insiders | 13.0% | 6.0% |
| Insider net buying, 12 months | – | −$986K |
| Short interest, % of float | – | 20.9% |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- EBS stock overview
- EBS income statement
- EBS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.